Atuzabrutinib | 1581714-49-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Atuzabrutinib
• 英文别名: (E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
• CAS: 1581714-49-9
• 化学式: C₃₀H₃₀FN₇O₂
• 分子量: 539.6
• InChiKey: KZMQPYCXSAGLTB-ZWUNQBBJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  40
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  123
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• SALTS AND SOLID FORM OF A BTK INHIBITOR
  申请人：PRINCIPIA BIOPHARMA INC.

  公开号：US20170065591A1

  公开（公告）日：2017-03-09

  Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.

  本文披露了制备2-[(3R)-3-[4-氨基-3-(2-氟-4-苯氧基苯基)吡唑[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环戊烷-3-基)哌嗪-1-基]戊-2-烯腈游离基（化合物（I））的过程，化合物（I）的盐和所述盐的固态形式。本文还披露了包括这些盐和固态形式的药物组合物，以及使用化合物（I）或其药学上可接受的盐治疗癌症、自身免疫和炎症性疾病的方法。
• TYROSINE KINASE INHIBITORS
  申请人：Principia Biopharma Inc.

  公开号：US20140303190A1

  公开（公告）日：2014-10-09

  The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

  本公开提供化合物及其药学上可接受的盐，它们是酪氨酸激酶抑制剂，特别是BLK、BMX、EGFR、HER2、HER4、ITK、TEC、BTK和TXK，因此可用于治疗通过抑制酪氨酸激酶治疗的疾病，如癌症和炎症性疾病，如关节炎等。还提供含有这些化合物及其药学上可接受的盐的药物组合物和制备这些化合物及其药学上可接受的盐的方法。
• Salts and solid form of a BTK inhibitor
  申请人：PRINCIPIA BIOPHARMA INC.

  公开号：US10092569B2

  公开（公告）日：2018-10-09

  Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.

  本文公开了制备 2-[(3R)-3-[4-氨基-3-(2-氟-4-苯氧基苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-甲酰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈游离碱（化合物(I)）、化合物(I)的盐和所述盐的固态形式的工艺。本文还公开了包含此类盐及其固态形式的药物组合物，以及使用化合物（I）或其药学上可接受的盐治疗癌症、自身免疫性疾病和炎症性疾病的方法。
• Treatment of pemphigus
  申请人：Principia Biopharma Inc.

  公开号：US10485797B2

  公开（公告）日：2019-11-26

  The present disclosure provides methods of treating with a BTK inhibitor a blistering disease, in particular pemphigus vulgaris or pemphigus folliaceous in a mammal, use of a BTK inhibitor as a replacement therapy for corticosteroid therapy for diseases treatable with a corticosteroid, such as autoimmune or inflammatory disease and in particular where corticosteroids are used as first or second line therapy, and pharmaceutical formulations comprising the same.

  本公开提供了用BTK抑制剂治疗哺乳动物的大疱性疾病，特别是寻常天疱疮或花斑丘疹性天疱疮的方法，用BTK抑制剂作为皮质类固醇疗法的替代疗法治疗可使用皮质类固醇治疗的疾病，如自身免疫性或炎症性疾病，特别是在皮质类固醇被用作一线或二线疗法的情况下，以及包含BTK抑制剂的药物制剂。
• TREATMENT OF PEMPHIGUS
  申请人：Principia Biopharma Inc.

  公开号：EP3233103B1

  公开（公告）日：2020-10-14